The United States is the world’s medicine chest because it rewards success. If our leaders take that away, we shouldn’t be surprised when innovation slows — and patients pay the price.
The death rate from cancer in the United States has fallen by more than one-third since 1991. HIV-related mortality has dropped ninefold since 1995. Death rates for Alzheimer’s, chronic respiratory diseases, and stroke have all declined in recent years, too.
These gains didn’t happen by accident. They’re the result of decades of medical innovation — from antiretroviral therapy drugs to breakthrough cancer treatments — that have helped people live longer, healthier lives.
These pharmaceutical breakthroughs have delivered enormous value beyond the bedside. By preventing hospitalizations, reducing complications, and enabling people to remain productive for longer, new medicines and treatments generate broadly shared benefits for society and the economy.
Now, some lawmakers are putting that progress at risk by trying to give the government more power over drug prices.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Price Controls Could Prevent the Next ‘Miracle Drug’
Sally Pipes and Wayne Winegarden
The United States is the world’s medicine chest because it rewards success. If our leaders take that away, we shouldn’t be surprised when innovation slows — and patients pay the price.
The death rate from cancer in the United States has fallen by more than one-third since 1991. HIV-related mortality has dropped ninefold since 1995. Death rates for Alzheimer’s, chronic respiratory diseases, and stroke have all declined in recent years, too.
These gains didn’t happen by accident. They’re the result of decades of medical innovation — from antiretroviral therapy drugs to breakthrough cancer treatments — that have helped people live longer, healthier lives.
These pharmaceutical breakthroughs have delivered enormous value beyond the bedside. By preventing hospitalizations, reducing complications, and enabling people to remain productive for longer, new medicines and treatments generate broadly shared benefits for society and the economy.
Now, some lawmakers are putting that progress at risk by trying to give the government more power over drug prices.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.